Alzheimers DiseaseNCT06484244
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
A study testing 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation in people with Alzheimers Disease and Mild Cognitive Impairment, run by Emory University at 1 site in United States.
Trial summary
In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. Read more about this study
- Who is it for?
- Ages 50 to 90 years
- Conditions the study is for
- Alzheimers Disease, Mild Cognitive Impairment
- What is being tested?
- 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Jul 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- AD and MCI will be defined through formal diagnosis provided by a board-certified Neurologist. Amnestic MCI will be defined using the AD Neuroimaging Initiative (ADNI) criteria. All MCI participants in ADNI are required to have an amnestic subtype defined as:
- Subjective memory concern or a memory problem noted by their partner
- Abnormal memory function documented by a specified education adjusted cutoff score on the delayed paragraph recall of the Anna Thompson story of the Logical Memory subtest from the Wechsler Memory Scale-Revised
- Mini-Mental State Exam (MMSE) score between 20 and 26 (inclusive). Exceptions may be made for subjects with less than 8 years of education at the discretion of the PI. (iv) Single or multi-domain amnestic MCI (both subtypes are at high risk for progression to AD)
- Clinical Dementia Rating (CDR) = 0.5 (Memory Box score must be at least 0.5)
- General functional performance sufficiently preserved
Show all 10Show fewer
- Evidence of impaired executive function based on Montreal Cognitive Assessment (MoCA) score 13-17
- Able to walk 10 or more feet without an assistive device
- Completed six grades of education or has a good work history (sufficient to exclude intellectual disabilities)
- Not hospitalized within the last 60 days
Who cannot join
- Acute medical illness requiring hospitalization
- Uncontrolled congestive heart failure
- History of stroke
- Inability to perform study procedures
- Medical or physical conditions that would preclude participation or walking (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity)
- On medications that could adversely affect cognition, eg: antipsychotics, opioids, stimulants, chemotherapy, anti-parkinsonian drugs (eg Levodopa), neurologic prescriptions to treat Multiple sclerosis and/or Parkinson's
Show all 9Show fewer
- Psychotic disorders
- Confounding neurologic conditions (e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness >30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae)
- Substance Use Disorder, Major Depressive and Generalized Anxiety Disorders within six months of evaluation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Emory Rehabilitation Hospital
Atlanta, Georgia, 30322
About this study
In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. It is also an important therapeutic target for exercise-based interventions to improve walking function. The overall goal of this study is to understand the effects of MCI and AD on locomotor adaptation and walking function.
Read the detailed description
In conjunction with cognitive impairments, older adults with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) show increased impairments in walking function throughout disease progression. The ability to walk without the risk of falling is necessary for independent community activity and participation for elderly individuals. However, the relationships between cognition, gait dysfunction, and fall risk in people with MCI and AD are poorly understood, warranting further study. The objective of this study is to test the researchers' central hypothesis that in people with MCI and AD, decreased capacity for locomotor adaptation can worsen disease progression, and lead to reduced motor-cognitive function, mobility, and quality of life.
Community-based walking function requires complex motor coordination, sensory feedback, dynamic balance, adaptation to changing environmental stimuli, while also engaging in attentional tasks such as crossing a busy street or talking over the phone. Unfortunately, cognitive dysfunction, the hallmark of MCI and AD, directly impacts the cognitive-motor neural resources needed to carry out activities of daily living. People with MCI and AD walk slower, fall more, and have deficits in gait performance variables such as stride symmetry, and step regularity. Importantly, gait disturbances have often been shown to precede cognitive decline. In this study, the researchers propose to test their hypothesis that a decline in locomotor adaptation capacity may explain gait and mobility deficits in people with MCI and AD. Locomotor adaptation is a fundamentally important process that enables humans to flexibility respond to environmental demands, enabling normal community walking function. Split-belt adaptation is a standardized, robust, well studied paradigm for quantifying a person's capacity for locomotor adaptation, but had not yet been evaluated in people with MCI and AD. Split-belt walking task assesses locomotor adaptation, i.e. the ability to adjust stepping movements to changing environmental demands via trial-and-error processing. The split-belt task is systematically assessed during treadmill walking, where the speed of each leg can be controlled independently such that one belt and the corresponding leg run at a different speed (e.g., twice as fast or a 2:1 speed ratio) than the other leg. In previous work, both the magnitude and rate of split-belt adaptation as well as de-adaptation (during the after-effect) have provided objective measures of an individual's locomotor adaptation capacity.
The researchers of this study hypothesize that decreased capacity for split-belt adaptation may be an important contributing factor and a potentially sensitive indicator of increased fall risk and cognitive decline in older individuals with MCI and AD.
The researchers will examine locomotor adaptation capacity with three study aims: Aims 1 and 2 are observational, assessing walking function among persons with MCI and AD and age-matched controls. In Aim 3, a clinical trial is performed to evaluate the feasibility of a split-belt walking intervention on walking function in older adults with MCI and AD. Ten participants (5 with MCI and 5 with AD) will complete 5 split-belt treadmill walking exercise sessions over a 2-week period. The primary and secondary outcome measures for this study are measured in evaluation sessions before (Pre-training) and after 5 training sessions (Post-training).
- Conditions
- Alzheimers Disease, Mild Cognitive Impairment
- Being tested
- 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
- Keywords
- walking function, gait disturbances, gait variability, locomotor adaptation
- Medical subject headings
- Alzheimer Disease, Cognitive Dysfunction, Mobility Limitation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
5 Sessions of Split-belt Treadmill-based Locomotor AdaptationOther
Participants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes).
| Study group | Role | What they receive |
|---|---|---|
| Split-beltTreadmill-based Locomotor Adaptation in Older Adults with MCI | Experimental | Older adults with mild cognitive impairment (MCI) complete 5 split-belt treadmill walking exercise sessions over a 2-week period. Receives: Other: 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation |
| Split-beltTreadmill-based Locomotor Adaptation in Older Adults with AD | Experimental | Older adults with Alzheimer's Disease (AD) complete 5 split-belt treadmill walking exercise sessions over a 2-week period. Receives: Other: 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Adaptation Magnitude Assessed as Peak Step Length Symmetry
Locomotor adaptation is the ability to adjust stepping movements to changing environmental demands via trial-and-error processing. Step length symmetry data from the split-belt phase will be used to evaluate each individual's locomotor adaptation magnitude capacity by assessing the peak step length symmetry in the early adaptation period.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Adaptation Rate Assessed as the Number of Steps to Reach Step Symmetry
The adaptation rate is assessed as the number of steps required to reach a plateau in step symmetry during late adaptation.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in 10-Meter Overground Walk Test
Gait speed is assessed with the 10-Meter Overground Walk Test. The 10-Meter Overground Walk Test is used to assess walking speed over a short distance. A 10 meter (m) walkway over solid flooring will be measured and marked at start (0 m), 2 m, 8 m, and finish (10 m). Participants will be asked to complete three trials of the 10 m walk at their comfortable self-selected walking speed. The time for the three trials for each speed will be averaged and gait speed converted to meters/second.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in 6-Minute Walk Test
Gait endurance is assessed with the 6-minute walk test. The 6-Minute Walk Test is a sub-maximal exercise test used to assess walking endurance. A walkway of a minimum 12 m over solid flooring will be measured and marked with a turn-around marked at either end of the walkway. The turn-around points will be approximately 49 inches (124 cm) wide with clear markings. A chair will be placed at one end of the walkway to allow for seated rest breaks if necessary. Prior to administering the test, the participant will be seated in the chair resting. The participant will then be asked to walk as far as possible in 6 minutes along the walkway using scripted instruction (see below). The distance (in meters) will be calculated by multiplying the number of total laps by 12 meters and adding the distance of the partial lap completed at the time the test ended.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Montreal Cognitive Assessment (MoCA) Score
MoCA is an instrument to screen for mild cognitive dysfunction, assessing the cognitive domains of attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Total scores range from 0 to 30 with higher scores indicating better cognitive function. A normal score is considered to be 26 or higher.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in NIH-EXAMINER n-back Task Accuracy
The NIH-EXAMINER assesses spatial working memory with the n-back tasks. The 1-back involves maintaining and updating one location at a time while two locations at a time are maintained and updated with the 2-back. During the n-back tasks, participants view a series of stimuli and press a button when a particular stimulus has been previously shown. The 1-back consists of one block of 30 trials, ten of which match the location of the previous square, and 20 that are in a different location. The 2-back consists of one block of 90 trials, 30 of which match the location of the square two before, and 60 that are in a different location. The score is calculated as the percentage of correct responses.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Secondary outcomes (10)
Change in De-adaptation Magnitude Assessed as Peak Step Length Symmetry
Step length symmetry data from the split-belt phase will be used to evaluate each individual's locomotor de-adaptation magnitude capacity by assessing the peak step length symmetry after treadmill belt speeds return to normal.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in De-adaptation Rate Assessed as the Number of Steps to Reach Step Symmetry
The de-adaptation rate is assessed as the number of steps required to reach a plateau in step symmetry after treadmill belt speeds return to normal.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Timed Up and Go (TUG) Test
The Timed Up and Go test assesses mobility, balance, walking ability, and fall risk in older adults. The participant will be asked to be seated in a standard height chair (seat height 46 cm, arm height 67 cm), placing his/her back against the chair and resting his/her arms on the chair's arms. The participant will be asked to get up from the chair, walk to a line 3 m from the edge of the chair, turn around at the line, walk back to the chair, and sit down. The test will be timed using a stopwatch from when the investigator says "Go" to when the participant's buttocks touches the chair upon return. Time of the test will be recorded for single and dual-task conditions.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Falls History
Falls incidence and risk is assessed as self-reported history of falls.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Stride Duration
Gait performance is assessed as gait cycle duration, which is the time in milliseconds (ms) for the same foot to contact the floor in consecutive footsteps.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Double-support Duration
Gait performance is assessed as double-support duration. Double-support is the time when both feet are contacting the ground and it increases as walking speed decreases.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Executive Index Score (EIS)
Cognition is assessed with the Executive Index Score (EIS) which is based on performance on Trail-Making Test Part B, Clock Drawing, Digit Span, Letter A Tapping, Serial 7 Subtraction, Letter Fluency and Abstraction items. The EIS is calculated by adding raw scores for the included tasks. Total scores range from 0 to 13 and higher scores indicate better cognitive function.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Trail Making Test Part B Score
In Part A of the Trail Making Test (TMT) participants are presented with a sheet of paper with 25 circles numbered 1 through 25. Participants are asked to draw lines connecting the circles in ascending order of the numbers. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 29 seconds. Times greater than 78 seconds indicate cognitive impairment.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Step Length
Gait performance is assessed with step length. Step length is the distance between heel of one foot to the heel print of the other foot, measured in feet.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Change in Step Length Variability
Gait performance is assessed with the variability of step length.
Measured: Baseline (Pre-training), Week 2 (Post-training)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2024
- Study start22 Jul 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimers DiseaseStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Principal investigator, Trisha Kesar, Emory University
- Investigators
- Trisha Kesar, PT, PhD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06484244
- Sponsor's protocol ID
- STUDY00006698
- Other IDs
- R21AG084231
- Status last verified
- Feb 2026
- First submitted
- 26 Jun 2024
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified demographic, clinical measures of walking and sensorimotor function, walking biomechanics, and electromyography (EMG) data that is collected during this study will be made available for sharing with the research community. All preprocessed data will be deposited to Distributed Archives for Neurophysiology Data Integration (DANDI) after the conclusion of the award period for this study.
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
- ClinicalTrials.gov ID
- NCT06484244
- Acronym / sponsor ID
- STUDY00006698
- Conditions
- Alzheimers Disease, Mild Cognitive Impairment
- Keywords
- walking function, gait disturbances, gait variability, locomotor adaptation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- 22 Jul 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 3 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In people with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), reduced capacity for locomotor adaptation is a fundamental but poorly understood mechanism that can be a sensitive biomarker of cognitive-motor impairments. It is also an important therapeutic target for exercise-based interventions to improve walking function. The overall goal of this study is to understand the effects of MCI and AD on locomotor adaptation and walking function.
Detailed description
In conjunction with cognitive impairments, older adults with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) show increased impairments in walking function throughout disease progression. The ability to walk without the risk of falling is necessary for independent community activity and participation for elderly individuals. However, the relationships between cognition, gait dysfunction, and fall risk in people with MCI and AD are poorly understood, warranting further study. The objective of this study is to test the researchers' central hypothesis that in people with MCI and AD, decreased capacity for locomotor adaptation can worsen disease progression, and lead to reduced motor-cognitive function, mobility, and quality of life.
Community-based walking function requires complex motor coordination, sensory feedback, dynamic balance, adaptation to changing environmental stimuli, while also engaging in attentional tasks such as crossing a busy street or talking over the phone. Unfortunately, cognitive dysfunction, the hallmark of MCI and AD, directly impacts the cognitive-motor neural resources needed to carry out activities of daily living. People with MCI and AD walk slower, fall more, and have deficits in gait performance variables such as stride symmetry, and step regularity. Importantly, gait disturbances have often been shown to precede cognitive decline. In this study, the researchers propose to test their hypothesis that a decline in locomotor adaptation capacity may explain gait and mobility deficits in people with MCI and AD. Locomotor adaptation is a fundamentally important process that enables humans to flexibility respond to environmental demands, enabling normal community walking function. Split-belt adaptation is a standardized, robust, well studied paradigm for quantifying a person's capacity for locomotor adaptation, but had not yet been evaluated in people with MCI and AD. Split-belt walking task assesses locomotor adaptation, i.e. the ability to adjust stepping movements to changing environmental demands via trial-and-error processing. The split-belt task is systematically assessed during treadmill walking, where the speed of each leg can be controlled independently such that one belt and the corresponding leg run at a different speed (e.g., twice as fast or a 2:1 speed ratio) than the other leg. In previous work, both the magnitude and rate of split-belt adaptation as well as de-adaptation (during the after-effect) have provided objective measures of an individual's locomotor adaptation capacity.
The researchers of this study hypothesize that decreased capacity for split-belt adaptation may be an important contributing factor and a potentially sensitive indicator of increased fall risk and cognitive decline in older individuals with MCI and AD.
The researchers will examine locomotor adaptation capacity with three study aims: Aims 1 and 2 are observational, assessing walking function among persons with MCI and AD and age-matched controls. In Aim 3, a clinical trial is performed to evaluate the feasibility of a split-belt walking intervention on walking function in older adults with MCI and AD. Ten participants (5 with MCI and 5 with AD) will complete 5 split-belt treadmill walking exercise sessions over a 2-week period. The primary and secondary outcome measures for this study are measured in evaluation sessions before (Pre-training) and after 5 training sessions (Post-training).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Split-beltTreadmill-based Locomotor Adaptation in Older Adults with MCI | Experimental | Other: 5 Sessions of Split-belt Treadmill-based Locomotor AdaptationOlder adults with mild cognitive impairment (MCI) complete 5 split-belt treadmill walking exercise sessions over a 2-week period. |
| Split-beltTreadmill-based Locomotor Adaptation in Older Adults with AD | Experimental | Other: 5 Sessions of Split-belt Treadmill-based Locomotor AdaptationOlder adults with Alzheimer's Disease (AD) complete 5 split-belt treadmill walking exercise sessions over a 2-week period. |
Who may qualify
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- AD and MCI will be defined through formal diagnosis provided by a board-certified Neurologist. Amnestic MCI will be defined using the AD Neuroimaging Initiative (ADNI) criteria. All MCI participants in ADNI are required to have an amnestic subtype defined as:
- Evidence of impaired executive function based on Montreal Cognitive Assessment (MoCA) score 13-17
- Able to walk 10 or more feet without an assistive device
- Completed six grades of education or has a good work history (sufficient to exclude intellectual disabilities)
- Not hospitalized within the last 60 days
Key exclusion criteria (9 listed)
- Acute medical illness requiring hospitalization
- Uncontrolled congestive heart failure
- History of stroke
- Inability to perform study procedures
- Medical or physical conditions that would preclude participation or walking (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 5 Sessions of Split-belt Treadmill-based Locomotor AdaptationParticipants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes). | Other | Split-beltTreadmill-based Locomotor Adaptation in Older Adults with AD, Split-beltTreadmill-based Locomotor Adaptation in Older Adults with MCI |
Primary outcome
Change in Adaptation Magnitude Assessed as Peak Step Length Symmetry
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Locomotor adaptation is the ability to adjust stepping movements to changing environmental demands via trial-and-error processing. Step length symmetry data from the split-belt phase will be used to evaluate each individual's locomotor adaptation magnitude capacity by assessing the peak step length symmetry in the early adaptation period.
Change in Adaptation Rate Assessed as the Number of Steps to Reach Step Symmetry
Time frame: Baseline (Pre-training), Week 2 (Post-training)
The adaptation rate is assessed as the number of steps required to reach a plateau in step symmetry during late adaptation.
Change in 10-Meter Overground Walk Test
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Gait speed is assessed with the 10-Meter Overground Walk Test. The 10-Meter Overground Walk Test is used to assess walking speed over a short distance. A 10 meter (m) walkway over solid flooring will be measured and marked at start (0 m), 2 m, 8 m, and finish (10 m). Participants will be asked to complete three trials of the 10 m walk at their comfortable self-selected walking speed. The time for the three trials for each speed will be averaged and gait speed converted to meters/second.
Change in 6-Minute Walk Test
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Gait endurance is assessed with the 6-minute walk test. The 6-Minute Walk Test is a sub-maximal exercise test used to assess walking endurance. A walkway of a minimum 12 m over solid flooring will be measured and marked with a turn-around marked at either end of the walkway. The turn-around points will be approximately 49 inches (124 cm) wide with clear markings. A chair will be placed at one end of the walkway to allow for seated rest breaks if necessary. Prior to administering the test, the participant will be seated in the chair resting. The participant will then be asked to walk as far as possible in 6 minutes along the walkway using scripted instruction (see below). The distance (in meters) will be calculated by multiplying the number of total laps by 12 meters and adding the distance of the partial lap completed at the time the test ended.
Change in Montreal Cognitive Assessment (MoCA) Score
Time frame: Baseline (Pre-training), Week 2 (Post-training)
MoCA is an instrument to screen for mild cognitive dysfunction, assessing the cognitive domains of attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Total scores range from 0 to 30 with higher scores indicating better cognitive function. A normal score is considered to be 26 or higher.
Change in NIH-EXAMINER n-back Task Accuracy
Time frame: Baseline (Pre-training), Week 2 (Post-training)
The NIH-EXAMINER assesses spatial working memory with the n-back tasks. The 1-back involves maintaining and updating one location at a time while two locations at a time are maintained and updated with the 2-back. During the n-back tasks, participants view a series of stimuli and press a button when a particular stimulus has been previously shown. The 1-back consists of one block of 30 trials, ten of which match the location of the previous square, and 20 that are in a different location. The 2-back consists of one block of 90 trials, 30 of which match the location of the square two before, and 60 that are in a different location. The score is calculated as the percentage of correct responses.
10 secondary outcomes
Change in De-adaptation Magnitude Assessed as Peak Step Length Symmetry
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in De-adaptation Rate Assessed as the Number of Steps to Reach Step Symmetry
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in Timed Up and Go (TUG) Test
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in Falls History
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in Stride Duration
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in Double-support Duration
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in Executive Index Score (EIS)
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in Trail Making Test Part B Score
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in Step Length
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Change in Step Length Variability
Time frame: Baseline (Pre-training), Week 2 (Post-training)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Individual participant dataSharing planned: Yes. Deidentified demographic, clinical measures of walking and sensorimotor function, walking biomechanics, and electromyography (EMG) data that is collected during this study will be made available for sharing with the research community. All preprocessed data will be deposited to Distributed Archives for Neurophysiology Data Integration (DANDI) after the conclusion of the award period for this study.
Related trials for Alzheimers Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trisha Kesar, PT, PhD principal investigator
Emory University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation in people with Alzheimers Disease and Mild Cognitive Impairment, run by Emory University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trisha Kesar, PT, PhD ((404) 712-5803, tkesar@emory.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Adaptation Magnitude Assessed as Peak Step Length Symmetry (time frame: Baseline (Pre-training), Week 2 (Post-training)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.